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of capecitabine administration cost, were derived from
DRG information issued by French Health Authorities.
For capecitabine, the administration cost (drug acquisi-
tion cost excluded) has been considered to be equal to 
the cost of an oncologist out-patient visit. RESULTS:
Efﬁcacy was assessed for 297 patients in the capecitabine
arm and for 299 patients in the FuFol arm based on 
an average follow-up of 165 days. The average costs for 
the management of metastatic colorectal cancer patients
with capecitabine and FuFol are respectively €4320 and
€10,311 (p < 0.001). Full administration costs (corre-
sponding to the drug acquisition cost plus the cost related
to the administration) are €3882 for capecitabine and
€9742 for FuFol (p < 0.001). Costs related to the treat-
ment of adverse events are €396 for capecitabine and
€537 for FuFol (p = 0.16). CONCLUSION: This cost
minimisation analysis shows that the use of capecitabine
results in very signiﬁcant savings on ﬁxed costs. Hospital
medical resources are becoming particularly scarce in
France. In this context, capecitabine is of high economic
interest for the treatment of metastatic colorectal cancer.
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OBJECTIVES: Evaluating the outcomes of prophylactic
care and estimating direct medical costs of CINV among
patients receiving emetogenic chemotherapy in Germany.
METHODS: Prospective, multi-center, cross-sectional,
cost-of-illness study (3 hospitals and 3 ofﬁce-based facil-
ities). Two hundred eight patients receiving level 4 or 5
emetogenic chemotherapy (Hesketh classiﬁcation) were
evaluable. Data were obtained from chart reviews and
patients’ diaries. We provide data on the subgroup of 137
patients who received chemotherapy at hospital (mean
age: 55 years; 61% male) and present costs from
providers’ perspective (hospital). RESULTS: Seventy-
three patients (53%) reported at least 1 episode of nausea
or vomiting, despite antiemetic prophylaxis. More
patients experienced delayed than acute CINV (50% vs.
20%) and more patients reported nausea than vomiting
(51% vs. 21%). Ninety percent and 71% of patients
received prophylactic antiemetic regimens for acute or
delayed CINV in compliance with ASCO (American
Society of Clinical Oncology) guidelines, respectively.
Twelve percent of patients receiving prophylaxis for
delayed symptoms according to ASCO guidelines experi-
enced delayed vomiting in contrast to 34% of the group
whose treatment did not follow the guidelines (p < 0.05).
One patient was rehospitalized due to CINV; 12 patients
received rescue medication at hospital. Mean direct
medical costs for antiemetic prophylaxis per patient and
treatment cycle were €34 (SD 11). Mean direct costs due
to CINV per patient and cycle were €15 (SD 81). Staff
time and material consumption associated with manag-
ing episodes of CINV was the main cost driver (92%).
Rescue medication (administered inside hospital) is
responsible for 8% of those costs. CONCLUSIONS: In
the hospital setting we found considerable room for
improvement in processes and outcomes of care regard-
ing guideline adherence for antiemetic prophylaxis of
delayed CINV. Aside from its clinical consequences,
CINV has an additional economic impact in oncology
centers. Improved CINV prophylaxis may potentially
offset some of costs of CINV treatment.
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OBJECTIVE: To estimate costs associated with manage-
ment of chemotherapy-induced toxicity with pemetrexed
compared with docetaxel as second-line chemotherapy
for advanced non-small cell lung cancer (NSCLC).
METHODS: Resource utilization data were analysed
from a multinational phase III randomised trial compar-
ing pemetrexed (ALIMTA®) with docetaxel (N = 571).
Costs included in this initial analysis were hospitalisa-
tions, transfusions, erythropoietin, granulocyte colony-
stimulating factors (GCSFs) and parenteral antibiotics.
Unit costs were sourced from UK National Health Service
(NHS) case mix data (2002) and national drug prices.
RESULTS: Efﬁcacy was shown to be similar with median
survival times of approximately 8 months for both arms,
although toxicity-related events and need for medical
management were lower for pemetrexed. CTC grade 3/4
neutropenia and neutropenic fever were signiﬁcantly
higher for docetaxel (40% vs. 5%, 13% vs. 2%, respec-
tively). Most other grade 3/4 toxicities, including
nausea/vomiting, diarrhoea, thrombocytopenia and
anaemia, occurred at low rates (£5%) and were similar
between treatment arms. The most common reasons for
drug-related hospitalisation for both arms were febrile
neutropenia and neutropenia (4 admissions on the peme-
trexed arm [£4730] vs. 42 on the docetaxel arm
